Intra Cellular Therapies reported $-72662000 in EBIT for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Acadia Pharmaceuticals ACAD:US $ -113016000 68.36M
Aptinyx Inc APTX:US $ -19379000 207K
Biocryst Pharmaceuticals BCRX:US $ -49957000 2.22M
Biogen BIIB:US $ 531.5M 11.7M
Bristol Myers Squibb BMY:US $ 3188M 399M
Cytokinetics CYTK:US $ -77857000 58.95M
Esperion Therapeutics ESPR:US $ -42989000 611K
Gilead Sciences GILD:US $ 2897M 1957M
Halozyme Therapeutics HALO:US $ 75.67M 19.14M
Intra Cellular Therapies ITCI:US $ -72662000 13.34M
JAZZ PHA JAZZ:US 87.55M 105.43M
Marinus Pharmaceuticals MRNS:US -16711000 10.4M
Minerva Neurosciences NERV:US $ -7989260 13.39M
Nektar Therapeutics NKTR:US $ -112910000 686K
Novartis NVS:US 3.15B 266M
Prothena PRTA:US -37944000 4.85M
Supernus Pharmaceuticals SUPN:US $ 1.97M 26.43M
United Therapeutics UTHR:US $ 288M 117.2M
Vanda Pharmaceuticals VNDA:US $ -7669000 36.1M